when will retatrutide be released VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide Phase 3: 60% Achieved

It promotes lipid mobilization from adipose tissue, enhances hepatic glucose modulation, and increases energy expenditure in ways that the GLP-1/GIP combination alone does not fully achieve

Susan Spratt, an endocrinologist and the senior medical director for the Population Health Management Office at Duke Health in North Carolina, questioned whether the increased risk was due to the rapid weight loss or some other mechanism of the drug

Focus: US Diabetes Patients Face Delays as Insurers Tighten Ozempic Coverage

A.Montrose-RafizadehC.et al

"The more they wanted, the more frustrated I would get." The 57-year-old power plant worker who lives near Santa Cruz, Calif., had already gotten a Zepbound prescription from his primary care doctor last December to treat the obstructive sleep apnea that was leaving him exhausted every morning

Lovelle also addresses concerns about GLP-1 side effects and their integration into broader care plans